BeiGene Rebuts Short-Seller Allegations, But Real Challenges May Lie Elsewhere
A report from a short-seller firm has put Beijing-based biotech bellwether BeiGene in an unwanted spotlight, prompting management to defend its record.
You may also be interested in...
Jiangsu Hengrui’s anti-PD-1 antibody is the latest to hit the immuno-oncology market in China, ensuring a fierce battle in pricing and reimbursement. Other recent new approvals include Pfizer’s antibacterial Zavicefta and a first-in-class topical treatment for psoriasis.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.